<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31652146</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-4058</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Applied immunohistochemistry &amp; molecular morphology : AIMM</Title><ISOAbbreviation>Appl Immunohistochem Mol Morphol</ISOAbbreviation></Journal><ArticleTitle>Neurofilament Immunohistochemistry Followed by Luxol Fast Blue, for Staining Axons and Myelin in the Same Paraffin Section of Spinal Cord.</ArticleTitle><Pagination><StartPage>562</StartPage><EndPage>565</EndPage><MedlinePgn>562-565</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/PAI.0000000000000814</ELocationID><Abstract><AbstractText>Many disorders of the central nervous system are characterized by both axonal pathology and demyelination. In assessing this concurrent pathology, techniques for staining axons or myelin are frequently used separately. Here we report the development of a combined immunohistochemical and tinctorial staining technique in which we have modified the Luxol fast blue myelin stain to be used in conjunction with a diaminobenzidine-based immunohistochemical stain for high molecular weight neurofilament (SMI-31). This modification of staining will have utility in experimental neuropathology laboratories investigating demyelination and axonal damage in human tissue and animal models.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moszczynski</LastName><ForeName>Alexander J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Molecular Medicine Research Group, Robarts Research Institute.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Volkening</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Molecular Medicine Research Group, Robarts Research Institute.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neurological Sciences, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strong</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Molecular Medicine Research Group, Robarts Research Institute.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neurological Sciences, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Appl Immunohistochem Mol Morphol</MedlineTA><NlmUniqueID>100888796</NlmUniqueID><ISSNLinking>1533-4058</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007211">Indoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>1328-51-4</RegistryNumber><NameOfSubstance UI="C018588">Luxol Fast Blue MBS</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007382" MajorTopicYN="N">Intermediate Filaments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009186" MajorTopicYN="N">Myelin Sheath</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013194" MajorTopicYN="N">Staining and Labeling</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31652146</ArticleId><ArticleId IdType="doi">10.1097/PAI.0000000000000814</ArticleId><ArticleId IdType="pii">00129039-202008000-00013</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhou T, Ahmad TK, Gozda K, et al. Implications of white matter damage in amyotrophic lateral sclerosis (review). Mol Med Rep. 2017;16:4379&#x2013;4392.</Citation></Reference><Reference><Citation>Mu J, Li M, Wang T, et al. Myelin damage in diffuse axonal injury. Front Neurosci. 2019;13:1&#x2013;11.</Citation></Reference><Reference><Citation>Strong MJ, Kesavapany S, Pant HC. The pathobiology of amyotrophic lateral sclerosis: a proteinopathy? J Neuropathol Exp Neurol. 2005;64:649&#x2013;664.</Citation></Reference><Reference><Citation>Schiffer D, Attanasio A, Migheli A, et al. Ubiquitinated dystrophic neurites suggest corticospinal derangement in patients with amyotrophic lateral sclerosis. Neurosci Lett. 1994;180:21&#x2013;24.</Citation></Reference><Reference><Citation>Hirano A. Neuropathology of ALS: an overview. Neurology. 2012;47(suppl 2):63S&#x2013;66S.</Citation></Reference><Reference><Citation>Van Tilborg E, van Kammen CM, De Theije CGM, et al. A quantitative method for microstructural analysis of myelinated axons in the injured rodent brain. Sci Rep. 2017;7:1&#x2013;11.</Citation></Reference><Reference><Citation>Luna L. Manual of Histologic Staining Methods of the Armed Forced Institute of Pathology, 3rd ed. New York, NY: McGraw-Hill; 1968.</Citation></Reference><Reference><Citation>Wisniewski HM, Shek JW, Gruca S, et al. Aluminum-induced neurofibrillary changes in axons and dendrites. Acta Neuropathol. 1984;63:190&#x2013;197.</Citation></Reference><Reference><Citation>Wisniewski HM, Terry RD, Hirano A. Neurofibrilary pathology. J Neuropathol Exp Neurol. 1970;29:163&#x2013;176.</Citation></Reference><Reference><Citation>Manetto V, Sternberger NH, Perry G, et al. Phosphorylation of neurofilaments is altered in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 1988;47:642&#x2013;653.</Citation></Reference><Reference><Citation>Hayashi S, Sakurai A, Amari M, et al. Pathological study of the diffuse myelin pallor in the anterolateral columns of the spinal cord in amyotrophic lateral sclerosis. J Neurol Sci. 2001;188:3&#x2013;7.</Citation></Reference><Reference><Citation>Johnson VE, Stewart W, Smith DH. Axonal pathology in traumatic brain injury. Exp Neurol. 2013;246:35&#x2013;43.</Citation></Reference><Reference><Citation>Haines JD, Inglese M, Casaccia P. Axonal damage in multiple sclerosis. Mt Sinai J Med. 2011;78:231&#x2013;243.</Citation></Reference><Reference><Citation>Muller-Wielsch KS, Cannella B, Raine CS. Multiple sclerosis: neurofilament pathology in spinal motor neurons. J Mult Scler. 2017;4:207.</Citation></Reference><Reference><Citation>McDonald JW, Belegu V. Demyelination and remyelination after spinal cord injury. J Neurotrauma. 2006;23:345&#x2013;359.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>